ClinicalTrials.gg
CompletedNCT04516382Updated Sep 16, 2021

Pharmacokinetics and Pharmacodynamics of Different PTG-300 Regimens in Healthy Volunteers

A Phase 1 interventional study of PTG-300 in Healthy Volunteers, sponsored by Protagonist Therapeutics, Inc.. Completed at 1 site in Australia. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-09-16.

Sponsored by Protagonist Therapeutics, Inc. · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Jan 2021, 5 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
Male
01

Study summary

To estimate the bioavailability of PTG-300 following subcutaneous and intramuscular administration in healthy volunteers.

Read the detailed description

This is a single center, open-label study in healthy males. Subjects will be screened for eligibility within 28 days of dosing.

Twelve subjects will receive single doses of the following treatments in a fixed sequence:

Treatment A: Intravenous injection of 1.5 mg PTG-300. Treatment B: 40 mg (40 mg/mL) PTG-300 administered subcutaneously. Treatment C: 40 mg (200 mg/mL) PTG-300 administered subcutaneously. Treatment D: 40 mg (40 mg/mL) PTG-300 administered intramuscularly.

There will be a washout period of at least 7 days between Treatment A and Treatment B and at least 12 days between Treatments B, C, and D.

Subjects' safety will be monitored, and blood samples will be collected for pharmacokinetics and pharmacodynamics (serum iron, serum ferritin, serum transferrin, and transferrin saturation [TSAT]).

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Protagonist Therapeutics, Inc. is the lead sponsor of 13 studies on the registry; none are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 1 (11%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male volunteers, age 18 to 65 years, inclusive.
  2. Subjects must have a (BMI) between 18 and 32 kg/m2 inclusive.
  3. Subjects must have clinical laboratory values within normal range as specified by the testing laboratory, unless deemed not by the Investigator.
  4. Agree to use a barrier method of from Day -2 to 90 days after the last dose of study drug.
  5. Subjects must have the ability and willingness to attend the necessary visits to the study center.

Exclusion criteria

Exclusion Criteria:

  1. History of endocrine, neurological, gastrointestinal, cardiovascular, haematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases.
  2. History of , with the exception of adequately treated non-melanomatous skin carcinoma.
  3. Mentally or legally incapacitated, has significant emotional problems at the time of Screening Visit or expected during the conduct of the study, or has a history of a clinically significant psychiatric disorder that would impact the subjects ability to participate in the trial according to the Investigator.
  4. Fever (body temperature >38°C) or symptomatic viral or bacterial infection within 2 weeks prior to screening; evidence of intestinal infection within 30 days prior to screening.
  5. History of severe allergic or anaphylactic reactions.
  6. A supine blood pressure outside the range of 90 to 139 mm Hg systolic and 50 to 89 mm Hg diastolic, OR heart rate (HR) >100 beats per minute at Screening and at Day -1.
  7. Laboratory values that are outside the normal range and considered clinically significant by the Investigator.
  8. Positive test for antibody, surface antigen or (HIV) antibody at Screening.
  9. Subjects considered at high risk of iron deficiency according to the Investigator.
  10. Subjects with iron deficiency as defined by a ferritin or transferrin saturation below the normal range
  11. Clinically significant abnormality on performed at the Screening Visit or prior to administration of the initial dose of study drug.
  12. (QTcF) greater than 450 msec at Screening.
  13. Subjects with a positive toxicology screening panel.
  14. Subjects with a history of substance abuse or dependency or history of recreational IV drug use (by self-declaration).
  15. Consumption of >14 alcohol units per week (where 1 unit = 284 mL of beer, 25 mL of 40% spirit, or a 125 mL glass of wine).
  16. Unable to refrain from or anticipates the use of any medications, including prescription and non-prescription drugs and herbal remedies (such as St. John's Wort [Hypericum perforatum]), beginning 14 days (or 5 half lives, whichever is longer) before administration of the initial dose of study drug and continuing throughout the study until the final study visit.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Intravenous

    PTG-300 Intravenous

    Drug: PTG-300

  • Experimental
    Subcutaneous Low Concentration

    PTG-300 Subcutaneous Low Concentration

    Drug: PTG-300

  • Experimental
    Subcutaneous High Concentration

    PTG-300 Subcutaneous High Concentration

    Drug: PTG-300

  • Experimental
    Intramuscular

    PTG-300 Intramuscular

    Drug: PTG-300

Interventions

06

What researchers measure

Primary outcomes

  1. Bioavailability of PTG-300

    Bioavailability (area under the plasma-concentration time) of PTG-300 following subcutaneous and intramuscular administration in healthy volunteers

    Time frame: Week 1

Secondary outcomes

  1. Serum Iron Pharmacodynamics of PTG-300

    Change from baseline in serum iron following subcutaneous and intramuscular administration in healthy volunteers

    Time frame: Week 1

  2. TSAT Pharmacodynamics of PTG-300

    Change from baseline in transferrin saturation (TSAT) following subcutaneous and intramuscular administration in healthy volunteers

    Time frame: Week 1

07

Study locations

1 site
  • Protagonist Clinical Center
    Melbourne, Australia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Jan 2021, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2020
First posted
Aug 18, 2020
StartActual
Sep 14, 2020
Primary completionActual
Jan 12, 2021
CompletionActual
Jun 30, 2021
Last update
Sep 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04516382
Lead sponsor
Protagonist Therapeutics, Inc.
Responsible party
Sponsor
First posted
Aug 18, 2020
Start date
Sep 14, 2020
Primary completion
Jan 12, 2021
Completion
Jun 30, 2021
Last update
Sep 16, 2021

Study contacts

Study Director
study director · Protagonist Therapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rusfertide

Start the discussion